Nasdaq: ELVN

Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker ELVN. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
ELVN
Exchange
Nasdaq
SEC CIK
1672619
Official filings
SEC EDGAR

Research ELVN

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Enliven Therapeutics, Inc.'s stock ticker?

Enliven Therapeutics, Inc. trades under the ticker symbol ELVN on Nasdaq. Its SEC Central Index Key (CIK) is 1672619.

Where can I read Enliven Therapeutics, Inc.'s SEC filings?

The ELVN SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Enliven Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze ELVN's financial statements?

The ELVN Financials page shows Enliven Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does ELVN compare with its peers and the market?

The ELVN Peer Comparison page lines Enliven Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.